Post Your Answer
2 years ago in Pharmacokinetics/Pharmacodynamics (PK/PD) , Physiology of Aging By Puneet Chadha
How does the physiological process of aging affect the pharmacokinetics and pharmacodynamics of atropine, and how should this inform clinical use?
For a pharmacology lecture, I need to explain the specific mechanisms behind age-related risks with atropine. I understand that renal clearance decreases, but what about volume of distribution for a lipophilic drug like atropine? How does reduced acetylcholine production or receptor density in the aging brain affect the drug's action? I'm looking for a clear, evidence-based explanation of the altered PK/PD profile in the elderly to teach rationale, not just empirical caution.
All Answers (1 Answers In All)
By Jeremy Answered 1 year ago
Aging fundamentally alters atropine's profile. Pharmacokinetically: While renal excretion of unchanged drug is minor, its hepatic metabolism (via esterases) can be impaired. More critically, its volume of distribution (Vd) increases due to a higher body fat-to-lean mass ratio in the elderly; atropine is lipophilic, so it sequesters in fat, leading to a prolonged half-life and risk of accumulation. Pharmacodynamically: There is an inherent increase in central nervous system (CNS) sensitivity. Age-related loss of cholinergic neurons and decreased muscarinic receptor density in the brain means even small anticholinergic insults can precipitate significant cognitive dysfunction. Furthermore, autonomic dysfunction common in the elderly makes the heart's response less predictable. This combined PK/PD shift narrows the therapeutic window dramatically, necessifying lower initial doses, longer intervals between doses, and vigilant monitoring for both inadequate effect and toxicity.
ÂReply to Jeremy
Related Questions